More Articles

Patients and Medical

Putting patients front and center

Andrew Stone, (Sep 20, 2019)

When it comes to access, pharma can only gain by starting with the patient, says Takeda’s Liz Lewis
Patients and Medical

Towards patient preferred trials

Katie Osborne, (Sep 18, 2019)

Putting the patient at the centre of clinical trials could be transformative
Patients and Medical

Design: Pharma’s next frontier

Lucy Fulford, (Sep 16, 2019)

Design Thinking and Human-Centric Design promise better outcomes and superior returns if Pharma can unlock its potential
Commercial

No patents. No launches. No stages. Welcome to modern pharma.

Paul Schrimpf, (Sep 3, 2019)

Winning in customer experience requires pharmaceutical companies to literally get off their own drugs, says Paul Schrimpf
Patients and Medical

Whose data is it anyway?

Andy stone, (Aug 30, 2019)

When cancer patient Pete started to look into who held records about his illness and treatment, mapping the journey of his data proved to be no easy feat.
Patients and Medical

Creating a Patient Trial Community

Katie Osborne, (Aug 13, 2019)

A pioneering project promises to transform patients’ clinical trials experience and help move the trials process forward
Patients and Medical

Creating a Patient Trial Community

adaptive, (Aug 13, 2019)

A pioneering project promises to transform patients’ clinical trials experience and help move the trials process forward
Patients and Medical

Unleashing AI’s potential in clinical trial recruitment

Katie Osborne, (Jul 29, 2019)

Multiple innovations using AI are transforming the trial recruitment process
Patients and Medical

Making it about the patient, with the patient

Danielle Barron, (Jul 26, 2019)

Danielle Barron speaks to Laurie Meyers, Genentech’s Head of Patient Engagement Operations, about what she learned while creating a new patient engagement function.
Access and Evidence

Putting The I in Pills

Izzy Gladstone, (Jun 27, 2019)

Individualised medicine has so far failed to live up to the hype but innovations in the field are on the cusp of disrupting the way pharma and healthcare develop and provide treatments.

Pages